) The Iowa Oncology Research Association (IORA) is a multidisciplinary consortium of six Iowa hospitals; their surgical, medical and radiation oncologists, internal medicine and family practice physicians and related non-physician cancer care staffs. Four of these hospitals are located in Des Moines, one in Mason City and one in Ottumwa. The IORA has been a principal member of the North Central Cancer Treatment Group (NCCTG) since 1979 and has secondary research bases with the Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Program (NSABP), Gynecologic Oncology Group (GOG) and Children?s Oncology Group (COG). The goals of IORA are: 1) Expand clinical research efforts in cancer treatment, cancer control, and cancer prevention in NCI approved clinical trials through the combined participation of its investigators and patient population; 2) Support the goals and work of research bases with involvement of IORA investigators, nurses, and clinical research associates in protocol development, committees and meetings; 3) Improve the quality of oncology care of Iowans by use of state-of-the-art treatment and cancer control protocols; 4) Diffuse the knowledge gained from clinical trials to physicians who provide care for non-protocol patients; 5) Sustain the valuable network of clinical cancer researchers and providers in Iowa who collaborate in NCI-approved clinical trials and other endeavors such as the NCI?s SEER program, the CDC?s NIOSH Demonstration Cancer Control Project for Farmers, and NCI Patterns of Care; 6) Improve community participation in prevention studies such as the NSABP Breast Cancer Prevention Trial (STAR) and the second SWOG Prostate Cancer Prevention Trial (SELECT) by utilizing recruitment strategies learned from IORA's successful implementation of the first SWOG Prostate Cancer Prevention Trial; 7) Increase primary care physician involvement in cancer prevention; 8) Develop strategies to increase minority involvement in cancer research keeping in mind that Iowa is 97% Caucasian and thus traditionally defined minority groups are infrequent in our population base. The recent addition of two residency program medical directors (family practice and internal medicine) to IORA membership will improve access to minority populations. The IORA has a proven tract record as an efficient and disciplined team of investigators who come from three strategically located Iowa communities. The organization is the link between six hospitals, eight major group practices and forty-nine physicians. The IORA will continue to enthusiastically emphasize quality in its research efforts if awarded a CCOP grant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035101-20
Application #
6758061
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
O'Mara, Ann M
Project Start
1995-06-01
Project End
2006-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
20
Fiscal Year
2004
Total Cost
$649,206
Indirect Cost
Name
Iowa Oncology Research Association
Department
Type
DUNS #
180870891
City
Des Moines
State
IA
Country
United States
Zip Code
50309
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76

Showing the most recent 10 out of 161 publications